Dengue virus infections in the first 2 years of life and the kinetics of transplacentally transferred dengue neutralizing antibodies in Thai children

Journal of Infectious Diseases

Volumn 194, Issue 11, 2006, Pages 1570-1576

  Pengsaa, Krisana ^a,d   Luxemburger, Christine ^c   Sabchareon, Arunee ^a   Limkittikul, Kriengsak ^a   Yoksan, Sutee ^a   Chambonneau, Laurent ^c   Chaovarind, Udom ^b   Sirivichayakul, Chukiat ^a   Lapphra, Keswadee ^a   Chanthavanich, Pornthep ^a   Lang, Jean ^c  

^a MAHIDOL UNIVERSITY   (Thailand)

^b RAJAVITHI HOSPITAL   (Thailand)

^c SANOFI PASTEUR   (France)

^d MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY;

ADOLESCENT; ADULT; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CORD SERUM; DENGUE; FEMALE; FEVER; HUMAN; HUMAN TISSUE; INFANT; INFECTION RATE; MALE; MATERNAL SERUM; PLACENTAL TRANSFER; PRIORITY JOURNAL; SEROTYPE; THAILAND;

ANTIBODIES, VIRAL; CHILD, PRESCHOOL; DENGUE; DENGUE VIRUS; ENDEMIC DISEASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FETAL BLOOD; FEVER OF UNKNOWN ORIGIN; HUMANS; IMMUNITY, MATERNALLY-ACQUIRED; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFANT; KINETICS; MOTHERS; NEUTRALIZATION TESTS; PROSPECTIVE STUDIES; QUESTIONNAIRES; THAILAND;

EID: 33845185764     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/508492     Document Type: Article

References (27)

1. Nimmannitya S. Clinical spectrum and management of dengue haemorrhagic fever. Southeast Asian J Trop Med Public Health 1987; 18: 392-7.
2. World Health Organization (WHO). Dengue haemorrhagic fever: diagnosis, treatment and control. 2nd ed. Geneva: WHO, 1997.
3. Kliks SC, Nisalak A, Brandt WE, Wahl L, Burke DS. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg 1989; 40:444-51.
4. Rigau-Perez JG, Clark GG, Gubler DJ, Reiter P, Sanders EJ, Vorndam AV. Dengue and dengue haemorrhagic fever. Lancet 1998; 352:971-7.
5. Halstead SB. Pathogenesis of dengue: challenges to molecular biology. Science 1988; 239:476-81.
6. Sullivan NJ. Antibody-mediated enhancement of viral disease. Curr Top Microbiol Immunol 2001; 260:145-69.
7. Barnes WJS, Rosen L. Fatal hemorrhagic disease and shock associated with primary dengue infection on a Pacific island. Am J Trop Med Hyg 1974; 23:495-506.
8. Scott RMcN, Nimmannitya S, Bancroft WH, Mansuwan P. Shock syndrome in primary dengue infection. Am J Trop Med Hyg 1976; 25:866-74.
9. Sriprom M, Pongsumpun P, Yoksan S, Barbazan P, Gonzalez JP, Tang IM. Dengue hemorrhagic fever in Thailand, 1998-2003: primary or secondary infection. Dengue Bull 2003; 27:39-45.
10. Mackenzie JS, Gubler DJ, Petersen LR. Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat Med 2004; 10:S98-109.
11. Pinheiro FP, Corber SJ. Global situation of dengue hemorrhagic fever and its emergence in the Americas. World Health Stat Q 1997; 50:161-9.
12. Halstead SB, Lan NT, Myint TT, et al. Dengue hemorrhagic fever in infants: research opportunities ignored. Emerg Infect Dis 2002; 8:1474-9.
13. Kalayanarooj S, Nimmannitya S. Clinical presentations of dengue hemorrhagic fever in infants compared to children. J Med Assoc Thai 2003;86:5673-80.
14. Sabchareon A, Lang J, Chanthavanich P, et al. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio and multiple doses. Am J Trop Med Hyg 2002; 66:264-72.
15. Monath TP, McCarthy K, Bedford P, et al. Clinical proof of principle for ChimeriVax™: recombinant live, attenuated vaccines against flavivirus infections. Vaccine 2002; 20:1004-18.
16. Edelman R, Wasserman SS, Bodison SA, et al. Phase 1 trial of 16 formulations of a tetravalent live attenuated dengue vaccine. Am J Trop Med Hyg 2003; 69(Suppl):48-60.
17. Sabchareon A, Lang J, Chanthavanich P, et al. Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children. Pediatr Infect Dis J 2004; 23:99-109.
18. Hombach J, Barrett AD, Cardosa MJ, et al. Review on flavivirus vaccine development. Proceedings of a meeting jointly organised by the World Health Organization and the Thai Ministry of Public Health, 26-27 April 2004, Bangkok, Thailand. Vaccine 2005; 23:2689-95.
19. Watanaveeradej V, Endy TP, Samakoses R, et al. Transplacentally transferred maternal-infant antibodies to dengue virus. Am J Trop Med Hyg 2003; 69:123-8.
20. Pengsaa K, Yoksan S, Limkittikul K, et al. Maternally transferred neutralising dengue antibodies in Thai infants: a pilot study. Ann Trop Paediatr 2003; 23:159-65.
21. Russell PK, Nisalak A, Sukhavachana P, Vivona S. A plaque reduction test for dengue virus neutralizing antibodies. J Immunol 1967; 99:285-90.
22. Clarke DH, Casals J. Techniques for hemagglutination and hemagglutination-inhibition with arthropod-borne viruses. Am J Trop Med Hyg 1958; 7:561-73.
23. Shu PY, Chen LK, Chang SF, et al. Dengue NS1-specific antibody response: isotype distribution and serotyping in patients with dengue fever and dengue hemorrhagic fever. J Med Virol 2000; 62:224-32.
24. Yamada KI, Takasaki T, Nawa M, Yabe S, Kurane I. Antibody responses determined for Japanese dengue fever patients by neutralization and hemagglutination inhibition assays demonstrate cross-reactivity between dengue and Japanese encephalitis viruses. Clin Diagn Lab Immunol 2003; 10:725-8.
25. Kliks SC, Nimmannitya S, Nisalak A, Burke DS. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg 1988; 38:411-9.
26. Gans HA, Arvin AM, Galinus J, Logan L, De Hovitz R, Maldonado Y. Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. JAMA 1998; 280:527-32.
27. American Academy of Pediatrics. Measles. In: Pickering LK, ed. Red book: 2003 report of the Committee on Infectious Diseases. 26th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2003:419-29.